Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed COO
Appointed director
BridgeBio Pharma, Inc. (BBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update - Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy , including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 , demonstrating a continued potentially best-in-class efficacy and well-tolerated safety profile, and a mean increase in annualized height velocity of 3.38cm/year with no treatment-related adverse events - Dosed the first participant in FORTIFY, a global Phase 3 study of BBP-418 in patients with limb girdle muscular dystrophy type 2I/R9 and met with the FDA to discuss the use of glycosylated alpha-dystroglycan levels as a surrogate endpoint; based on this ..."
07/17/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
03/09/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several Underwriters listed on Schedule I thereto",
"Opinion of Goodwin Procter LLP regarding the issue of Common Stock being registered",
"BridgeBio Pharma Announces Proposed Public Offering of Common Stock",
"BridgeBio Pharma Announces Pricing of Public Offering of Common Stock"
03/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events",
"Corporate presentation, furnished herewith"
02/23/2023 8-K Quarterly results, Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update"
12/06/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
09/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/04/2022 8-K Quarterly results
07/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/24/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
12/27/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study"
12/16/2021 8-K Quarterly results
11/18/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing"
11/04/2021 8-K Quarterly results
Docs: "BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update"
10/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors"
08/23/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors"
08/13/2021 8-K Quarterly results
06/22/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/15/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
01/29/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 29, 2021 BridgeBio Pharma, Inc. Delaware 001-38959 84-1850815 421 Kipling Street Palo Alto, CA 94301 391-9740 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under th...",
"Indenture, by and between BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee",
"Form of Confirmation for Capped Call Transactions"
01/26/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Purchase Agreement, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several Initial Purchasers",
"BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes",
"BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy